When confronted with advanced cancer
Select Appropriate Therapy
What is Deep Genomic Analysis ?
Deep genomic analysis is a method of detecting the four main classes of modifications known to drive cancer growth: base substitutions, insertions and deletions, copy number alterations (CNAs), and fusions. This test can be done on FFPE tissue, peripheral whole blood, bone marrow aspirate, or extracted nucleic acid, among other specimen types. When compared to traditional molecular testing, deep genomic analysis helps you better anticipate response or resistance to targeted and immunotherapies for more advanced cancer patients.
The Advantage of CellDx™
Based on the particular genomic profile of each patient’s cancer, CellDx is designed to offer physicians with clinically meaningful information — both to select appropriate therapy for patients and to comprehend results with evidence of resistance.
When
Diagnosed with cancer and advised molecular profiling of the tumor to explore targeted therapies / immunotherapies.
Features
- Targeted Therapy : Evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors.
- Immunotherapy : Helps inform immunotherapy decisions by including genomic signatures such as Microsatellite Instability (MSI), Tumor Mutational Burden (TMB) and PD-L1 status.
- Simplified Report : All results are provided in a simplified report, with indications for approved therapies and genomic highlights.
- 511 Genes (SNVs, CNAs, Fusions and Indels).
Features
- Targeted Therapy : Evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors.
- Immunotherapy : Helps inform immunotherapy decisions by including genomic signatures such as microsatellite instability (MSI), tumor mutational burden (TMB) and PDL1 status.
- Simplified Report : All results are provided in a simplified report, with indications for approved therapies and genomic highlights.
- 452 Genes (SNVs, CNAs, Fusions and Indels).
Biomarker-based Drug Indications
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
EGFR exon 19 deletions / exon 21 L858R |
Gefitinib, Erlotinib, Afatinib, Dacomitinib, Osimertinib |
|
EGFR exon 20 insertion mutation |
Amivantamab |
|
EGFR T790M |
Osimertinib |
|
KRAS G12C |
Sotorasib |
|
ALK rearrangements |
Alectinib, Crizotinib, Ceritinib, Lorlatinib, Brigatinib |
|
BRAF V600E |
Dabrafenib in comibation with Trametinib |
|
ROS1 rearrangements |
Entrectinib, Crizotinib |
|
RET rearrangements |
Selpercatinib, Pralsetinib |
|
MET exon 14 skipping mutation |
Capmatinib, Tepotinib |
|
NTRK fusions |
Larotrectinib, Entrectinib |
|
PDL1 |
Pembrolizumab, Nivolumab, Atezolizumab |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
KRAS wild-type |
Cetuximab, Panitumumab |
|
MSI-H/dMMR |
Nivolumab + Ipilimumab or Pembrolizumab |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
ERBB2 (HER2) amplification |
Lapatinib, Neratinib, Trastuzumab, Ado-trastuzumab emtansine, Pertuzumab, Margetuximab, Tucatinib, Fam-trastuzumab deruxtecan |
|
PDL1 (SP142) |
Atezolizumab |
|
BRCA1/2 alterations |
Olaparib, Talazoparib |
|
PIK3CA |
Alpelisib |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
BRCA1/2 alterations |
Olaparib, Rucaparib, Niraparib |
|
HRD deficient tumors |
Niraparib |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
BRAF V600E |
Dabrafenib or Vemurafenib |
|
BRAF V600E or V600K |
Trametinib or Cobimetinib in combination with Dabrafenib or Vemurafenib |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
NTRK |
Entrectinib, Larotrectinib |
|
MSI-H/dMMR |
Pembrolizumab |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
FGFR2, FGFR3 gene alterations |
Erdafitinib |
|
PDL1 |
Pembrolizumab, Atezolizumab |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
ERBB2 (HER2) overexpression |
Trastuzumab, Fam-Trastuzumab deruxtecan |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
FGFR2 (fusion / rearrangement) |
Infigratinib, Pemigatinib |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
BRCA1/2 mutation |
Olaparib |
| Biomarker | US FDA – Approved Therapy |
|---|---|
|
HRR deficient tumors, BRCA1/2 mutations |
Olaparib |
Want to delve a little deeper?
If you have questions or would like to know more about test performance, download the brochure.
We’re here to assist you
If you have any questions or want to learn more, please contact us or visit our FAQs.